ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Kisqali 200 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains ribociclib succinate, equivalent to 200 mg ribociclib.

Excipients with known effect

Each film-coated tablet contains 0.344 mg soya lecithin.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet.

Light greyish violet, unscored, round, curved with bevelled edges (approximate diameter: 11.1 mm), debossed with “RIC” on one side and “NVR” on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

4.2 Posology and method of administration

Treatment with Kisqali should be initiated by a physician experienced in the use of anticancer therapies.

Posology

The recommended dose is 600 mg (three 200 mg film-coated tablets) of ribociclib once daily for 21 consecutive days followed by 7 days off treatment, resulting in a complete cycle of 28 days. The treatment should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.

Kisqali should be used together with 2.5 mg letrozole or another aromatase inhibitor or with 500 mg fulvestrant.

When Kisqali is used in combination with an aromatase inhibitor, the aromatase inhibitor should be taken orally once daily continuously throughout the 28-day cycle. Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for additional details.
When Kisqali is used in combination with fulvestrant, fulvestrant is administered intramuscularly on days 1, 15 and 29, and once monthly thereafter. Please refer to the SmPC of fulvestrant for additional details.

Treatment of pre- and perimenopausal women with the approved Kisqali combinations should also include an LHRH agonist in accordance with local clinical practice.

Kisqali can be taken with or without food (see section 4.5). Patients should be encouraged to take their dose at approximately the same time each day, preferably in the morning. If the patient vomits after taking the dose or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.

**Dose modifications**
Management of severe or intolerable adverse reactions (ARs) may require temporary dose interruption, reduction or discontinuation of Kisqali. If dose reduction is required, the recommended dose reduction guidelines are listed in Table 1.

### Table 1  **Recommended dose modification guidelines**

<table>
<thead>
<tr>
<th></th>
<th>Kisqali Dose</th>
<th>Number of 200 mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting dose</td>
<td>600 mg/day</td>
<td>3</td>
</tr>
<tr>
<td>First dose reduction</td>
<td>400 mg/day</td>
<td>2</td>
</tr>
<tr>
<td>Second dose reduction</td>
<td>200 mg*/day</td>
<td>1</td>
</tr>
</tbody>
</table>

* If further dose reduction below 200 mg/day is required, the treatment should be permanently discontinued.

Tables 2, 3, 4, 5 and 6 summarise recommendations for dose interruption, reduction or discontinuation of Kisqali in the management of specific ARs. The clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment (see section 4.4).
Complete blood counts (CBC) should be performed before initiating treatment with Kisqali. After initiating treatment CBC should be monitored every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, then as clinically indicated.

Table 2  Dose modification and management – Neutropenia

<table>
<thead>
<tr>
<th>Neutropenia</th>
<th>Grade 1 or 2* (ANC 1000/mm$^3$ - ≤LLN)</th>
<th>Grade 3* (ANC 500 - &lt;1000/mm$^3$)</th>
<th>Grade 3* febrile neutropenia**</th>
<th>Grade 4* (ANC &lt;500/mm$^3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No dose adjustment is required</td>
<td>Dose interruption until recovery to grade ≤2. Resume Kisqali at the same dose level. If toxicity recurs at grade 3: dose interruption until recovery to grade ≤2, then resume Kisqali and reduce by 1 dose level.</td>
<td>Dose interruption until recovery to grade ≤2. Resume Kisqali and reduce by 1 dose level.</td>
<td>Dose interruption until recovery to grade ≤2. Resume Kisqali and reduce by 1 dose level.</td>
</tr>
</tbody>
</table>

* Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events)
** Grade 3 neutropenia with a single fever >38.3°C (or above 38°C for more than one hour and/or concurrent infection)
ANC = absolute neutrophil count; LLN = lower limit of normal
Liver function tests (LFTs) should be performed before initiating treatment with Kisqali. After initiating treatment LFTs should be performed every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, then as clinically indicated. If grade ≥2 abnormalities are noted, more frequent monitoring is recommended.

Table 3  Dose modification and management – Hepatobiliary toxicity

<table>
<thead>
<tr>
<th>Grade 1* (&gt; ULN – 3 x ULN)</th>
<th>Grade 2* (&gt;3 to 5 x ULN)</th>
<th>Grade 3* (&gt;5 to 20 x ULN)</th>
<th>Grade 4* (&gt;20 x ULN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST and/or ALT elevations from baseline**, without increase in total bilirubin above 2 x ULN</td>
<td>No dose adjustment is required.</td>
<td>Baseline grade &lt;2: Dose interruption until recovery to ≤ baseline grade, then resume Kisqali at same dose level. If grade 2 recurs, resume Kisqali at next lower dose level.</td>
<td>Dose interruption of Kisqali until recovery to ≤ baseline grade, then resume at next lower dose level. If grade 3 recurs, discontinue Kisqali.</td>
</tr>
<tr>
<td>Combined elevations in AST and/or ALT together with total bilirubin increase, in the absence of cholestasis</td>
<td>If patients develop ALT and/or AST &gt;3 x ULN along with total bilirubin &gt;2 x ULN irrespective of baseline grade, discontinue Kisqali.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events)  
** Baseline = prior to treatment initiation  
ULN = upper limit of normal

ECG should be assessed before initiating treatment with Kisqali. After initiating treatment, ECG should be repeated at approximately day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated. In case of QTcF prolongation during treatment, more frequent ECG monitoring is recommended.

Table 4  Dose modification and management – QT prolongation

| ECGs with QTcF >480 msec | 1. The dose should be interrupted.  
2. If QTcF prolongation resolves to <481 msec, resume treatment at the next lower dose level.  
3. If QTcF ≥481 msec recurs, interrupt dose until QTcF resolves to <481 msec and then resume Kisqali at the next lower dose level. |
|--------------------------|----------------------------------------------------------------------------|
| ECGs with QTcF >500 msec | If QTcF is greater than 500 msec, interrupt Kisqali until QTcF is <481 msec then resume Kisqali at next lower dose level.  
If QTcF interval prolongation to greater than 500 msec or greater than 60 msec change from baseline occurs in combination with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia, permanently discontinue Kisqali. |
**Table 5**  Dose modification and management – ILD/pneumonitis

<table>
<thead>
<tr>
<th>Grade 1* (asymptomatic)</th>
<th>Grade 2* (symptomatic)</th>
<th>Grade 3 or 4* (severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ILD/pneumonitis</strong></td>
<td>No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</td>
<td>Dose interruption until recovery to grade ≤1, then resume Kisqali at the next lower dose level*.</td>
</tr>
</tbody>
</table>

*Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events)
**An individualised benefit-risk assessment should be performed when considering resuming Kisqali ILD = interstitial lung disease

**Table 6**  Dose modification and management – Other toxicities*

<table>
<thead>
<tr>
<th>Other toxicities</th>
<th>Grade 1 or 2**</th>
<th>Grade 3**</th>
<th>Grade 4**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</td>
<td>Dose interruption until recovery to grade ≤1, then resume Kisqali at the same dose level. If grade 3 recurs, resume Kisqali at the next lower dose level.</td>
<td>Discontinue Kisqali.</td>
</tr>
</tbody>
</table>

* Excluding neutropenia, hepatotoxicity, QT interval prolongation and ILD/pneumonitis.
**Grading according to CTCAE Version 4.03 (CTCAE = Common Terminology Criteria for Adverse Events)

Refer to the SmPC for the co-administered aromatase inhibitor, fulvestrant or LHRH agonist for dose modification guidelines and other relevant safety information in the event of toxicity.

**Dose modification for use of Kisqali with strong CYP3A4 inhibitors**
Concomitant use of strong CYP3A4 inhibitors should be avoided and an alternative concomitant medicinal product with less potential to inhibit CYP3A4 inhibition should be considered. If patients must be given a strong CYP3A4 inhibitor concomitantly with ribociclib, the Kisqali dose should be reduced to 400 mg once daily (see section 4.5).

In patients who have had their dose reduced to 400 mg ribociclib daily and in whom initiation of co-administration of a strong CYP3A4 inhibitor cannot be avoided, the dose should be further reduced to 200 mg.

In patients who have had their dose reduced to 200 mg ribociclib daily and in whom initiation of co-administration of a strong CYP3A4 inhibitor cannot be avoided, Kisqali treatment should be interrupted.

Due to inter-patient variability, the recommended dose adjustments may not be optimal in all patients, therefore close monitoring of signs of toxicity is recommended. If the strong inhibitor is discontinued, the Kisqali dose should be changed to the dose used prior to the initiation of the strong CYP3A4 inhibitor after at least 5 half-lives of the strong CYP3A4 inhibitor (see sections 4.4, 4.5 and 5.2).
Special populations

Renal impairment
No dose adjustment is necessary in patients with mild or moderate renal impairment. A starting dose of 200 mg is recommended in patients with severe renal impairment. Kisqali has not been studied in breast cancer patients with severe renal impairment (see sections 4.4, 5.1 and 5.2).

Hepatic impairment
No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). Patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) can have increased (less than 2-fold) exposure to ribociclib and the starting dose of 400 mg Kisqali once daily is recommended (see section 5.2).

Paediatric population
The safety and efficacy of Kisqali in children and adolescents aged below 18 years have not been established. No data are available.

Elderly
No dose adjustment is required in patients over 65 years of age (see section 5.2).

Method of administration
Kisqali should be taken orally once daily with or without food. The tablets should be swallowed whole and should not be chewed, crushed or split prior to swallowing. No tablet should be ingested if it is broken, cracked or otherwise not intact.

4.3 Contraindications
Hypersensitivity to the active substance or to peanut, soya or any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use
Critical visceral disease
The efficacy and safety of ribociclib have not been studied in patients with critical visceral disease.

Neutropenia
Based on the severity of the neutropenia, treatment with Kisqali may have to be interrupted, reduced or discontinued as described in Table 2 (see sections 4.2 and 4.8).

Hepatobiliary toxicity
Liver function tests should be performed before initiating treatment with Kisqali. After initiating treatment, liver function should be monitored (see sections 4.2 and 4.8).

Based on the severity of the transaminase elevations, treatment with Kisqali may have to be interrupted, reduced or discontinued as described in Table 3 (see sections 4.2 and 4.8). Recommendations for patients who have elevated AST/ALT grade ≥ 3 at baseline have not been established.

QT interval prolongation
In study E2301 (MONALEESA-7), a QTcF interval increase >60 msec from baseline was observed in 14/87 (16.1%) patients receiving Kisqali plus tamoxifen and in 18/245 (7.3%) patients receiving Kisqali plus a non-steroidal aromatase inhibitor (NSAI). Kisqali is not recommended to be used in combination with tamoxifen (see sections 4.8 and 5.1).
ECG should be assessed before initiating treatment. Treatment with Kisqali should be initiated only in patients with QTcF values less than 450 msec. ECG should be repeated at approximately day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated (see sections 4.2 and 4.8).

Appropriate monitoring of serum electrolytes (including potassium, calcium, phosphorus and magnesium) should be performed before initiating treatment, at the beginning of the first 6 cycles and then as clinically indicated. Any abnormality should be corrected before initiating treatment with Kisqali and during treatment with Kisqali.

The use of Kisqali should be avoided in patients who already have or who are at significant risk of developing QTc prolongation. This includes patients:
- with long QT syndrome;
- with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias;
- with electrolyte abnormalities.

The use of Kisqali with medicinal products known to prolong QTc interval and/or strong CYP3A4 inhibitors should be avoided as this may lead to clinically meaningful prolongation of the QTcF interval (see sections 4.2, 4.5 and 5.1). If treatment with a strong CYP3A4 inhibitor cannot be avoided, the dose should be reduced to 400 mg once daily (see sections 4.2 and 4.5).

Based on the observed QT prolongation during treatment, treatment with Kisqali may have to be interrupted, reduced or discontinued as described in Table 4 (see sections 4.2, 4.8 and 5.2).

**Severe cutaneous reactions**

Toxic epidermal necrolysis (TEN) has been reported with Kisqali treatment. If signs and symptoms suggestive of severe cutaneous reactions (e.g. progressive widespread skin rash often with blisters or mucosal lesions) appear, Kisqali should be discontinued immediately.

**Interstitial lung disease/pneumonitis**

ILD/pneumonitis has been reported with CDK4/6 inhibitors including Kisqali. In the 3 phase III clinical studies (MONALEESA-2 [A2301], MONALEESA-7 [E2301-NSAI] and MONALEESA-3 [F2301]), ILD (any grade 0.3%, including 0.1% grade 3) was reported in the Kisqali-treated group, with no cases in the placebo-treated group. Pneumonitis (any grade 0.6%, versus 0.4%) was reported in the Kisqali- and placebo-treated groups, respectively, with no grade 3 or 4 events in either treatment group.

Based on the severity of the ILD/pneumonitis, which may be fatal, Kisqali may require dose interruption, reduction or discontinuation as described in Table 5 (see section 4.2).

Patients should be monitored for pulmonary symptoms indicative of ILD/pneumonitis which may include hypoxia, cough and dyspnoea and dose modifications should be managed in accordance with Table 5 (see section 4.2).

**Blood creatinine increase**

Ribociclib may cause blood creatinine increase as an inhibitor of the renal transporters organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1), which are involved in the active secretion of creatinine from the proximal tubules (see section 4.5). In case of blood creatinine increase while on treatment, it is recommended that further assessment of the renal function be performed to exclude renal impairment.
CYP3A4 substrates

Ribociclib is a strong CYP3A4 inhibitor at the 600 mg dose and a moderate CYP3A4 inhibitor at the 400 mg dose. Thus, ribociclib may interact with medicinal products which are metabolised via CYP3A4, which may lead to increased serum concentrations of CYP3A4 substrates (see section 4.5). Caution is recommended in case of concomitant use with sensitive CYP3A4 substrates with a narrow therapeutic index and the SmPC of the other product should be consulted for the recommendations regarding co-administration with CYP3A4 inhibitors.

Renal impairment

The recommended starting dose of 200 mg for patients with severe renal impairment is estimated to result in approximately 45% lower exposure compared with the standard starting dose in patients with normal renal function. The efficacy at this starting dose has not been studied. Caution should be used in patients with severe renal impairment with close monitoring for signs of toxicity (see sections 4.2 and 5.2).

Women of childbearing potential

Women of childbearing potential should be advised to use an effective method of contraception while taking Kisqali and for at least 21 days after the last dose (see section 4.6).

Soya lecithin

Kisqali contains soya lecithin. Patients who are hypersensitive to peanut or soya should not take Kisqali (see section 4.3).

4.5 Interaction with other medicinal products and other forms of interaction

Substances that may increase ribociclib plasma concentrations

Ribociclib is primarily metabolised by CYP3A4. Therefore, medicinal products that can influence CYP3A4 enzyme activity may alter the pharmacokinetics of ribociclib. Co-administration of the strong CYP3A4 inhibitor ritonavir (100 mg twice daily for 14 days) with a single 400 mg dose of ribociclib increased ribociclib exposure (AUC_{inf}) and the peak concentration (C_{max}) in healthy subjects 3.2 and 1.7-fold, respectively, relative to a single 400 mg ribociclib dose given alone. C_{max} and AUC_{last} for LEQ803 (a prominent metabolite of ribociclib accounting for less than 10% of parent exposure) decreased by 96% and 98%, respectively.

The concomitant use of strong CYP3A4 inhibitors including, but not limited to, the following must be avoided: clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir, ritonavir, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, verapamil and voriconazole (see section 4.4). Alternative concomitant medicinal products with less potential to inhibit CYP3A4 should be considered and patients should be monitored for ribociclib-related ARs (see sections 4.2, 4.4 and 5.2).

If co-administration of Kisqali with a strong CYP3A4 inhibitor cannot be avoided, the dose of Kisqali should be reduced as described in section 4.2. However, there are no clinical data with these dose adjustments. Due to inter-patient variability, the recommended dose adjustments may not be optimal in all patients, therefore close monitoring for ribociclib-related ARs is recommended. In the event of ribociclib-related toxicity, the dose should be modified or treatment should be interrupted until toxicity is resolved (see sections 4.2 and 5.2). If the strong CYP3A4 inhibitor is discontinued, and after at least 5 half-lives of the CYP3A4 inhibitor (refer to the SmPC of the CYP3A4 inhibitor in question), Kisqali should be resumed at the same dose used prior to the initiation of the strong CYP3A4 inhibitor.
Physiologically-based pharmacokinetic simulations suggested that at a 600 mg dose of ribociclib, a moderate CYP3A4 inhibitor (erythromycin) may increase ribociclib steady-state C\textsubscript{max} and AUC 1.2-fold and 1.3-fold, respectively. For patients who had their ribociclib dose reduced to 400 mg once daily, the increase of the steady-state C\textsubscript{max} and AUC was estimated to be 1.4- and 2.1-fold, respectively. The effect at the 200 mg once-daily dose was predicted to be a 1.7- and 2.8-fold increase, respectively. No dose adjustments of ribociclib are required at initiation of treatment with mild or moderate CYP3A4 inhibitors. However, monitoring of ribociclib-related ARs is recommended.

Patients should be instructed to avoid grapefruit or grapefruit juice. These are known to inhibit cytochrome CYP3A4 enzymes and may increase the exposure to ribociclib.

**Substances that may decrease ribociclib plasma concentrations**

Co-administration of the strong CYP3A4 inducer rifampicin (600 mg daily for 14 days) with a single 600 mg dose of ribociclib decreased the ribociclib AUC\textsubscript{inf} and C\textsubscript{max} by 89% and 81%, respectively, relative to a single 600 mg ribociclib dose given alone in healthy subjects. LEQ803 C\textsubscript{max} increased 1.7-fold and AUC\textsubscript{inf} decreased by 27%, respectively. The concomitant use of strong CYP3A4 inducers may therefore lead to decreased exposure and consequently a risk for lack of efficacy. The concomitant use of strong CYP3A4 inducers should be avoided, including, but not limited to, phenytoin, rifampicin, carbamazepine and St John’s Wort (*Hypericum perforatum*). An alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered.

The effect of a moderate CYP3A4 inducer on ribociclib exposure has not been studied. Physiologically-based pharmacokinetic simulations suggested that a moderate CYP3A4 inducer (efavirenz) may decrease steady-state ribociclib C\textsubscript{max} and AUC by 51% and 70%, respectively. The concomitant use of moderate CYP3A4 inducers may therefore lead to decreased exposure and consequently a risk for impaired efficacy, in particular in patients treated with ribociclib at 400 mg or 200 mg once daily.

**Substances that may have plasma concentrations altered by Kisqali**

Ribociclib is a moderate to strong CYP3A4 inhibitor and may interact with medicinal substrates that are metabolised via CYP3A4, which can lead to increased serum concentrations of the concomitantly used medicinal product.

Co-administration of midazolam (CYP3A4 substrate) with multiple doses of Kisqali (400 mg) increased the midazolam exposure by 280% (3.80-fold) in healthy subjects, compared with administration of midazolam alone. Simulations using physiologically-based pharmacokinetic models suggested that Kisqali given at the clinically relevant dose of 600 mg is expected to increase the midazolam AUC by 5.2-fold. Therefore, in general, when ribociclib is co-administered with other medicinal products, the SmPC of the other medicinal product must be consulted for the recommendations regarding co-administration with CYP3A4 inhibitors. Caution is recommended in case of concomitant use with sensitive CYP3A4 substrates with a narrow therapeutic index (see section 4.4). The dose of a sensitive CYP3A4 substrate with a narrow therapeutic index, including but not limited to alfentanil, ciclosporin, everolimus, fentanyl, sirolimus and tacrolimus, may need to be reduced as ribociclib can increase their exposure.

Concomitant administration of ribociclib at the 600 mg dose with the following CYP3A4 substrates should be avoided: alfuzosin, amiodarone, cisapride, pimozide, quinidine, ergotamine, dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, midazolam, triazolam.

Co-administration of caffeine (CYP1A2 substrate) with multiple doses of Kisqali (400 mg) increased the caffeine exposure by 20% (1.20-fold) in healthy subjects, compared with administration of caffeine alone. At the clinically relevant dose of 600 mg, simulations using PBK models predicted only weak inhibitory effects of ribociclib on CYP1A2 substrates (<2-fold increase in AUC).
Substances that are substrates of transporters

*In vitro* evaluations indicated that ribociclib has a potential to inhibit the activities of drug transporters P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 and BSEP. Caution and monitoring for toxicity are advised during concomitant treatment with sensitive substrates of these transporters which exhibit a narrow therapeutic index, including but not limited to digoxin, pitavastatin, pravastatin, rosuvastatin and metformin.

**Drug-food interactions**

Kisqali can be administered with or without food (see sections 4.2 and 5.2).

**Medicinal products that elevate gastric pH**

Ribociclib exhibits high solubility at or below pH 4.5 and in bio-relevant media (at pH 5.0 and 6.5). Co-administration of ribociclib with medicinal products that elevate the gastric pH was not evaluated in a clinical study; however, altered ribociclib absorption was not observed in population pharmacokinetic and non-compartmental pharmacokinetic analyses.

**Drug-drug interaction between ribociclib and letrozole**

Data from a clinical study in patients with breast cancer and population pharmacokinetic analysis indicated no drug interaction between ribociclib and letrozole following co-administration of these medicinal products.

**Drug-drug interaction between ribociclib and anastrozole**

Data from a clinical study in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and anastrozole following co-administration of these medicinal products.

**Drug-drug interaction between ribociclib and fulvestrant**

Data from a clinical study in patients with breast cancer indicated no clinically relevant effects of fulvestrant on ribociclib exposure following co-administration of these medicinal products.

**Drug-drug interaction between ribociclib and tamoxifen**

Data from a clinical study in patients with breast cancer indicated that tamoxifen exposure was increased approximately 2-fold following co-administration of ribociclib and tamoxifen.

**Drug-drug interactions between ribociclib and oral contraceptives**

Drug-drug interaction studies between ribociclib and oral contraceptives have not been conducted (see section 4.6).

**Anticipated interactions**

*Anti-arrhythmic medicinal products and other medicinal products that may prolong the QT interval*

Co-administration of Kisqali with medicinal products with a known potential to prolong the QT interval such as anti-arrhythmic medicinal products (including, but not limited to, amiodarone, disopyramide, procainamide, quinidine and sotalol), and other medicinal products that are known to prolong the QT interval (including, but not limited to, chloroquine, halofantrine, clarithromycin, ciprofloxacin, levofloxacin, azithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozone and intravenous ondansetron) should be avoided (see section 4.4). Kisqali is also not recommended to be used in combination with tamoxifen (see sections 4.1, 4.4 and 5.1).
4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Pregnancy status should be verified prior to starting treatment with Kisqali.

Women of childbearing potential who are receiving Kisqali should use effective contraception (e.g. double-barrier contraception) during therapy and for at least 21 days after stopping treatment with Kisqali.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Based on findings in animals, ribociclib can cause foetal harm when administered to a pregnant woman (see section 5.3). Kisqali is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is not known if ribociclib is present in human milk. There are no data on the effects of ribociclib on the breast-fed infant or the effects of ribociclib on milk production. Ribociclib and its metabolites readily passed into the milk of lactating rats. Patients receiving Kisqali should not breast-feed for at least 21 days after the last dose.

Fertility

There are no clinical data available regarding effects of ribociclib on fertility. Based on animal studies, ribociclib may impair fertility in males of reproductive potential (see section 5.3).

4.7 Effects on ability to drive and use machines

Kisqali may have minor influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines in case they experience fatigue, dizziness or vertigo during treatment with Kisqali (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

The most common adverse reactions (ARs) (reported at a frequency ≥20%) in the pooled dataset for which the frequency for Kisqali plus any combination exceeds the frequency for placebo plus any combination were neutropenia, infections, nausea, fatigue, diarrhoea, leukopenia, vomiting, headache, constipation, alopecia, cough, rash, back pain, anaemia and abnormal liver function tests.

The most common grade 3/4 ARs (reported at a frequency of ≥2%) in the pooled dataset for which the frequency for Kisqali plus any combination exceeds the frequency for placebo plus any combination were neutropenia, leukopenia, abnormal liver function tests, lymphopenia, infections, back pain, anaemia, fatigue, hypophosphataemia and vomiting.

Dose reduction due to adverse events, regardless of causality, occurred in 39.5% of patients receiving Kisqali in the phase III clinical studies regardless of the combination and permanent discontinuation was reported in 8.7% of patients receiving Kisqali and any combination in the phase III clinical studies.
Tabulated list of adverse reactions

The overall safety evaluation of Kisqali is based on the pooled dataset from 1,065 patients who received Kisqali in combination with endocrine therapy (N=582 in combination with an aromatase inhibitor and N=483 in combination with fulvestrant) and who were included in the randomised, double-blind, placebo-controlled phase III clinical studies (MONALEESA-2, MONALEESA-7 NSAI subgroup and MONALEESA-3) in HR-positive, HER2-negative advanced or metastatic breast cancer. Additional ADRs were identified post-marketing.

The median duration of exposure to study treatment across the pooled phase III studies dataset was 19.2 months, with 61.7% patients exposed ≥12 months.

Adverse reactions from the phase III clinical studies (Table 7) are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).
Table 7  Adverse reactions observed in the three phase III clinical studies and during post-marketing experience

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
</tr>
<tr>
<td>Infections¹</td>
<td>Very common</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Neutropenia, leukopenia, anaemia, lymphopenia</td>
<td>Very common</td>
</tr>
<tr>
<td>Thrombocytopenia, febrile neutropenia</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td></td>
</tr>
<tr>
<td>Hypocalcaemia, hypokalaemia, hypophosphataemia</td>
<td>Very common</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Headache, dizziness</td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>Very common</td>
</tr>
<tr>
<td>Common</td>
<td></td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Lacrimation increased, dry eye</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Dyspnoea, cough</td>
<td>Very common</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Nausea, diarrhoea, vomiting, constipation, abdominal pain², stomatitis, dyspepsia</td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Hepatotoxicity³</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Alopecia, rash⁴, pruritus</td>
<td></td>
</tr>
<tr>
<td>Dry skin, erythema, vitiligo</td>
<td>Very common</td>
</tr>
<tr>
<td>Toxic epidermal necrolysis (TEN)*</td>
<td>Not known</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
</tr>
<tr>
<td>Fatigue, peripheral oedema, pyrexia, asthenia</td>
<td>Very common</td>
</tr>
<tr>
<td>Oropharyngeal pain, dry mouth</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
</tr>
<tr>
<td>Abnormal liver function tests⁵</td>
<td></td>
</tr>
<tr>
<td>Blood creatinine increased, electrocardiogram QT prolonged</td>
<td>Very common</td>
</tr>
</tbody>
</table>

¹ Infections: urinary tract infections, respiratory tract infections, gastroenteritis, sepsis (<1%).
² Abdominal pain: abdominal pain, abdominal pain upper.
³ Hepatotoxicity: hepatic cytolysis, hepatocellular injury, drug-induced liver injury (<1%), hepatotoxicity, hepatic failure, autoimmune hepatitis (single case).
⁴ Rash: rash, rash maculopapular, rash pruritic.
⁵ Abnormal liver function tests: ALT increased, AST increased, blood bilirubin increased.

* Adverse reactions reported during post-marketing experience. These are derived from spontaneous reports for which it is not always possible to reliably establish frequency or a causal relationship to exposure to the medicinal product.
Description of selected adverse reactions

**Neutropenia**
Neutropenia was the most frequently reported adverse reaction (75.4%) and a grade 3 or 4 decrease in neutrophil counts (based on laboratory findings) was reported in 62.0% of patients receiving Kisqali plus any combination in the phase III studies.

Among the patients who had grade 2, 3 or 4 neutropenia, the median time to onset was 17 days, for those patients who had an event. The median time to resolution of grade ≥3 (to normalisation or grade <3) was 12 days in the Kisqali plus any combination arms following treatment interruption and/or reduction and/or discontinuation. Febrile neutropenia was reported in about 1.7% of patients exposed to Kisqali in the phase III studies. Patients should be instructed to report any fever promptly.

Based on its severity, neutropenia was managed by laboratory monitoring, dose interruption and/or dose modification. Treatment discontinuation due to neutropenia was low (0.8%) (see sections 4.2 and 4.4).

**Hepatobiliary toxicity**
In the phase III clinical studies, hepatobiliary toxicity events occurred in a higher proportion of patients in the Kisqali plus any combination arms compared with the placebo plus any combination arms (27.3% versus 19.6%, respectively), with more grade 3/4 adverse events reported in the patients treated with Kisqali plus any combination (13.2% versus 6.1%, respectively). Increases in transaminases were observed. Grade 3 or 4 increases in ALT (11.2% versus 1.7%) and AST (7.8% versus 2.1%) were reported in the Kisqali and placebo arms, respectively. Concurrent elevations in ALT or AST greater than three times the upper limit of normal and total bilirubin greater than two times the upper limit of normal, with normal alkaline phosphatase, in the absence of cholestasis occurred in 6 patients (4 patients in Study A2301 [MONALEESA-2], whose levels recovered to normal within 154 days and 2 patients in Study F2301 [MONALEESA-3], whose levels recovered to normal in 121 and 532 days, respectively, after discontinuation of Kisqali). There were no such cases reported in Study E2301 (MONALEESA-7).

Dose interruptions and/or adjustments due to hepatobiliary toxicity events were reported in 12.3% of Kisqali plus any combination treated patients, primarily due to ALT increased (7.9%) and/or AST increased (7.3%). Discontinuation of treatment with Kisqali plus any combination due to abnormal liver function tests or hepatotoxicity occurred in 2.4% and 0.3% of patients respectively (see sections 4.2 and 4.4).

In the phase III clinical studies, 70.9% (90/127) of grade 3 or 4 ALT or AST elevation events occurred within the first 6 months of treatment. Among the patients who had grade 3 or 4 ALT/AST elevation, the median time to onset was 92 days for the Kisqali plus any combination arms. The median time to resolution (to normalisation or grade ≤2) was 21 days in the Kisqali plus any combination arms.

**QT prolongation**
In study E2301 (MONALEESA-7), the observed mean QTcF increase from baseline was approximately 10 msec higher in the tamoxifen plus placebo subgroup compared with the NSAI plus placebo subgroup, suggesting that tamoxifen alone had a QTcF prolongation effect which can contribute to the QTcF values observed in the Kisqali plus tamoxifen group. In the placebo arm, a QTcF interval increase of >60 msec from baseline occurred in 6/90 (6.7%) patients receiving tamoxifen and in no patients receiving a NSAI (see section 5.2). A QTcF interval increase of >60 msec from baseline was observed in 14/87 (16.1%) patients receiving Kisqali plus tamoxifen and in 18/245 (7.3%) patients receiving Kisqali plus a NSAI. Kisqali is not recommended to be used in combination with tamoxifen (see section 5.1).
In the phase III clinical studies 9.3% of patients in the Kisqali plus aromatase inhibitor or fulvestrant arms and 3.5% in the placebo plus aromatase inhibitor or fulvestrant arms had at least one event of QT interval prolongation (including ECG QT prolonged and syncope). Review of ECG data showed 15 patients (1.4%) had >500 msec post-baseline QTcF value, and 61 patients (5.8%) had a >60 msec increase from baseline in QTcF intervals. There were no reported cases of torsade de pointes. Dose interruptions/adjustments were reported in 2.9% of Kisqali plus aromatase inhibitor or fulvestrant treated patients due to electrocardiogram QT prolonged and syncope.

The analysis of ECG data showed 55 patients (5.2%) and 12 patients (1.5%) with at least one >480 msec post-baseline QTcF for the Kisqali plus aromatase inhibitor or fulvestrant arms and the placebo plus aromatase inhibitor or fulvestrant arms, respectively. Amongst the patients who had QTcF prolongation >480 msec, the median time to onset was 15 days regardless of the combination and these changes were reversible with dose interruption and/or dose reduction (see sections 4.2, 4.4 and 5.2).

**Patients with renal impairment**

In the three pivotal studies, 341 patients with mild renal impairment and 97 patients with moderate renal impairment were treated with ribociclib. No patient with severe renal impairment was enrolled (see section 5.1). There was a correlation between the degree of renal impairment at baseline and blood creatinine values during the treatment. Slightly increased rates of QT prolongation and thrombocytopenia were observed in patients with mild or moderate renal impairment. For monitoring and dose adjustment recommendations for these toxicities see sections 4.2. and 4.4.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

There is only limited experience with reported cases of overdose with Kisqali. In the event of an overdose, symptoms such as nausea and vomiting may occur. In addition, haematological (e.g. neutropenia, thrombocytopenia) toxicity and possible QTc prolongation may occur. General supportive care should be initiated in all cases of overdose as necessary.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EF02

**Mechanism of action**

Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC₅₀) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-cyclins and play a crucial role in signalling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).

*In vitro*, ribociclib decreased pRb phosphorylation, leading to arrest in the G1 phase of the cell cycle, and reduced cell proliferation in breast cancer cell lines. *In vivo*, treatment with single-agent ribociclib led to tumour regressions which correlated with inhibition of pRb phosphorylation.
In vivo studies using patient-derived oestrogen receptor-positive breast cancer xenograft model combinations of ribociclib and antioestrogens (i.e. letrozole) resulted in superior tumour growth inhibition with sustained tumour regression and delayed tumour regrowth after stopping dosing compared to each substance alone. Additionally, in vivo antitumour activity of ribociclib in combination with fulvestrant was assessed in immune-deficient mice bearing the ZR751 ER+ human breast cancer xenografts and the combination with fulvestrant resulted in complete tumour growth inhibition.

When tested in a panel of breast cancer cell lines with known ER status, ribociclib demonstrated to be more efficacious in ER+ breast cancer cell lines than in the ER- ones. In the preclinical models tested so far, intact pRb was required for ribociclib activity.

Cardiac electrophysiology
Serial, triplicate ECGs were collected following a single dose and at steady state to evaluate the effect of ribociclib on the QTc interval in patients with advanced cancer. A pharmacokinetic-pharmacodynamic analysis included a total of 997 patients treated with ribociclib at doses ranging from 50 to 1200 mg. The analysis suggested that ribociclib causes concentration-dependent increases in the QTc interval. The estimated QTcF mean change from baseline for 600 mg Kisqali in combination with NSAI or fulvestrant was 22.0 msec (90% CI: 20.56, 23.44) and 23.7 msec (90% CI: 22.31, 25.08), respectively at the geometric mean Cmax at steady-state compared to 34.7 msec (90% CI: 31.64, 37.78) in combination with tamoxifen (see section 4.4).

Clinical efficacy and safety
Study CLEE011A2301 (MONALEESA-2)
Kisqali was evaluated in a randomised, double-blind, placebo-controlled, multicentre phase III clinical study in the treatment of postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease in combination with letrozole versus letrozole alone.

A total of 668 patients were randomised in a 1:1 ratio to receive either Kisqali 600 mg and letrozole (n=334) or placebo and letrozole (n=334), stratified according to the presence of liver and/or lung metastases (Yes [n=292 (44%)] vs No [n=376 (56%)]). Demographics and baseline disease characteristics were balanced and comparable between study arms. Kisqali was given orally at a dose of 600 mg daily for 21 consecutive days followed by 7 days off treatment in combination with letrozole 2.5 mg once daily for 28 days. Patients were not allowed to cross over from placebo to Kisqali during the study or after progression of disease.

Patients enrolled in this study had a median age of 62 years (range 23 to 91). 44.2% patients were aged 65 years and older, including 69 patients older than 75 years. The patients included were Caucasian (82.2%), Asian (7.6%), and Black (2.5%). All patients had an ECOG performance status of 0 or 1. In the Kisqali arm 46.6% of patients had received chemotherapy in the neoadjuvant or adjuvant setting and 51.3% had received antihormonal therapy in the neoadjuvant or adjuvant setting prior to study entry. 34.1% of patients were de novo. 22.0% of patients had bone-only disease and 58.8% of patients had visceral disease. Patients with prior (neo)adjuvant therapy with anastrozole or letrozole must have completed this therapy at least 12 months before study randomisation.

Primary analysis
The primary endpoint for the study was met at the planned interim analysis conducted after observing 80% of targeted progression-free survival (PFS) events using Response Evaluation Criteria in Solid Tumours (RECIST v1.1), based on the investigator assessment in the full population (all randomised patients), and confirmed by a blinded independent central radiological assessment.

The efficacy results demonstrated a statistically significant improvement in PFS in patients receiving Kisqali plus letrozole compared to patients receiving placebo plus letrozole in the full analysis set (hazard ratio of 0.556, 95% CI: 0.429, 0.720, one sided stratified log-rank test p-value 0.00000329) with clinically meaningful treatment effect.
The global health status/QoL data showed no relevant difference between the Kisqali plus letrozole arm and the placebo plus letrozole arm.

A more mature update of efficacy data (02 January 2017 cut-off) is provided in Tables 8 and 9.

Median PFS was 25.3 months (95% CI: 23.0, 30.3) for ribociclib plus letrozole treated patients and 16.0 months (95% CI: 13.4, 18.2) for patients receiving placebo plus letrozole. 54.7% of patients receiving ribociclib plus letrozole were estimated to be progression-free at 24 months compared with 35.9% in the placebo plus letrozole arm.

**Table 8**  MONALEESA-2 - Efficacy results (PFS) based on investigator radiological assessment (02 January 2017 cut-off)

<table>
<thead>
<tr>
<th></th>
<th>Updated analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kisqali plus letrozole</td>
</tr>
<tr>
<td></td>
<td>N=334</td>
</tr>
<tr>
<td>Progression-free survival</td>
<td></td>
</tr>
<tr>
<td>Median PFS [months] (95% CI)</td>
<td>25.3 (23.0-30.3)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.568 (0.457-0.704)</td>
</tr>
<tr>
<td>p-value*</td>
<td>9.63×10^8</td>
</tr>
</tbody>
</table>

CI=confidence interval; N=number of patients
*a p-value is obtained from the one-sided stratified log-rank test.

**Figure 1**  MONALEESA-2 - Kaplan-Meier plot of PFS based on investigator assessment (02 January 2017 cut-off)

- Censoring times
  - Ribociclib (N=334)
  - Placebo (N=334)

- No of events- Ribociclib: 140, Placebo: 205
- Hazard Ratio = 0.568; 95% CI [0.457, 0.704]
- Kaplan-Meier median - Ribociclib: 25.3 months; Placebo: 16.0 months
- Log rank p-value = 9.63×10^8

<table>
<thead>
<tr>
<th>Time (Months)</th>
<th>Ribociclib</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>334</td>
<td>334</td>
</tr>
<tr>
<td>2</td>
<td>294</td>
<td>279</td>
</tr>
<tr>
<td>4</td>
<td>277</td>
<td>265</td>
</tr>
<tr>
<td>6</td>
<td>257</td>
<td>239</td>
</tr>
<tr>
<td>8</td>
<td>240</td>
<td>219</td>
</tr>
<tr>
<td>10</td>
<td>227</td>
<td>196</td>
</tr>
<tr>
<td>12</td>
<td>207</td>
<td>179</td>
</tr>
<tr>
<td>14</td>
<td>196</td>
<td>156</td>
</tr>
<tr>
<td>16</td>
<td>188</td>
<td>138</td>
</tr>
<tr>
<td>18</td>
<td>176</td>
<td>124</td>
</tr>
<tr>
<td>20</td>
<td>164</td>
<td>110</td>
</tr>
<tr>
<td>22</td>
<td>132</td>
<td>93</td>
</tr>
<tr>
<td>24</td>
<td>97</td>
<td>63</td>
</tr>
<tr>
<td>26</td>
<td>46</td>
<td>34</td>
</tr>
<tr>
<td>28</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>30</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>32</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>34</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of patients still at risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
</tr>
<tr>
<td>Ribociclib</td>
</tr>
<tr>
<td>Placebo</td>
</tr>
</tbody>
</table>

18
A series of pre-specified subgroup PFS analyses was performed based on prognostic factors and baseline characteristics to investigate the internal consistency of treatment effect. A reduction in the risk of disease progression or death in favour of the Kisqali plus letrozole arm was observed in all individual patient subgroups of age, race, prior adjuvant or neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease. This was evident for patients with liver and/or lung metastases (HR of 0.561 [95% CI: 0.424, 0.743], median progression-free survival [mPFS] 24.8 months for Kisqali plus letrozole versus 13.4 months for letrozole alone), or without liver and/or lung metastases (HR of 0.597 [95% CI: 0.426, 0.837], mPFS 27.6 months versus 18.2 months).

Updated results for overall response and clinical benefit rates are displayed in Table 9.

### Table 9  MONALEESA-2 - Efficacy results (ORR, CBR) based on investigator assessment (02 January 2017 cut-off)

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Kisqali plus letrozole (%, 95% CI)</th>
<th>Placebo plus letrozole (%, 95% CI)</th>
<th>p-value&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full analysis set</strong></td>
<td>N=334</td>
<td>N=334</td>
<td></td>
</tr>
<tr>
<td>Overall response rate&lt;sup&gt;a&lt;/sup&gt;</td>
<td>42.5 (37.2, 47.8)</td>
<td>28.7 (23.9, 33.6)</td>
<td>9.18 × 10^-5</td>
</tr>
<tr>
<td>Clinical benefit rate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>79.9 (75.6, 84.2)</td>
<td>73.1 (68.3, 77.8)</td>
<td>0.018</td>
</tr>
<tr>
<td>Patients with measurable disease</td>
<td>n=257</td>
<td>n=245</td>
<td></td>
</tr>
<tr>
<td>Overall response rate&lt;sup&gt;a&lt;/sup&gt;</td>
<td>54.5 (48.4, 60.6)</td>
<td>38.8 (32.7, 44.9)</td>
<td>2.54 × 10^-4</td>
</tr>
<tr>
<td>Clinical benefit rate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>80.2 (75.3, 85.0)</td>
<td>71.8 (66.2, 77.5)</td>
<td>0.018</td>
</tr>
</tbody>
</table>

<sup>a</sup> ORR: Overall response rate = proportion of patients with complete response + partial response

<sup>b</sup> CBR: Clinical benefit rate = proportion of patients with complete response + partial response (+ stable disease or non-complete response/Non-progressive disease ≥ 24 weeks)

<sup>c</sup> p-values are obtained from one-sided Cochran-Mantel-Haenszel chi-square test

### Final OS analysis

The results from this final OS analysis on the overall study population are provided in Table 10 and Figure 2.

### Table 10  MONALEESA-2 - Efficacy results (OS) (10 June 2021 cut-off)

<table>
<thead>
<tr>
<th>Overall survival, overall study population</th>
<th>Kisqali plus letrozole</th>
<th>Placebo plus letrozole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of events – n [%]</td>
<td>N=334</td>
<td>N=334</td>
</tr>
<tr>
<td>Median OS [months] (95% CI)</td>
<td>63.9 (52.4, 71.0)</td>
<td>51.4 (47.2, 59.7)</td>
</tr>
<tr>
<td>Hazard ratio&lt;sup&gt;a&lt;/sup&gt; (95% CI)</td>
<td>0.765 (0.628, 0.932)</td>
<td>0.004</td>
</tr>
<tr>
<td>OS event-free rate, (%) (95% CI)</td>
<td>86.6 (82.3, 89.9)</td>
<td>85.0 (80.5, 88.4)</td>
</tr>
<tr>
<td>24 months</td>
<td>52.3 (46.5, 57.7)</td>
<td>43.9 (38.3, 49.4)</td>
</tr>
<tr>
<td>60 months</td>
<td>44.2 (38.5, 49.8)</td>
<td>32.0 (26.8, 37.3)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Hazard ratio is obtained from stratified Cox PH model

<sup>b</sup> p value is obtained from the one-sided log rank test (p<0.0219 to claim superior efficacy).

Stratification performed by lung and/or liver metastases status as per IRT.
Figure 2  MONALEESA-2 - Kaplan-Meier plot of OS in overall population (10 June 2021 cut-off)

Log-rank test and Cox PH model are stratified by liver and/or lung metastasis as per IRT. One sided P-value is obtained from stratified log rank test.

Study CLEE011E2301 (MONALEESA-7)
Kisqali was evaluated in a randomised, double-blind, placebo-controlled, multicentre phase III clinical study in the treatment of pre- and perimenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with a NSAI or tamoxifen plus goserelin versus placebo in combination with a NSAI or tamoxifen plus goserelin. Patients in MONALEESA-7 had not received prior endocrine treatment in the advanced breast cancer setting.

A total of 672 patients were randomised in a 1:1 ratio to receive either Kisqali 600 mg plus NSAI/tamoxifen plus goserelin (n=335) or placebo plus NSAI/tamoxifen plus goserelin (n=337), stratified according to: the presence of liver and/or lung metastases (Yes [n=344 (51.2%)] versus No [n=328 (48.8%)]), prior chemotherapy for advanced disease (Yes [n=120 (17.9%)] versus No [n=552 (82.1%)]), and endocrine combination partner (NSAI and goserelin [n=493 (73.4%)] versus tamoxifen and goserelin [n=179 (26.6%)]). Demographics and baseline disease characteristics were balanced and comparable between study arms. Kisqali was given orally at a dose of 600 mg daily for 21 consecutive days followed by 7 days off treatment in combination with NSAI (letrozole 2.5 mg or anastrozole 1 mg) or tamoxifen (20 mg) orally once daily for 28 days, and goserelin (3.6 mg) subcutaneously every 28 days, until disease progression or unacceptable toxicity. Patients were not allowed to cross over from placebo to Kisqali during the study or after disease progression. Switching the endocrine combination partners was also not permitted.

Patients enrolled in this study had a median age of 44 years (range 25 to 58) and 27.7% of patients were younger than 40 years old. The majority of patients included were Caucasian (57.7%), Asian (29.5%) or Black (2.8%) and nearly all patients (99.0%) had a baseline ECOG performance status of 0 or 1. Prior to study entry, of these 672 patients, 14% of patients had received prior chemotherapy for metastatic disease, 32.6% of patients had received chemotherapy in the adjuvant and 18.0% in the neoadjuvant setting; 39.6% had received endocrine therapy in the adjuvant setting and 0.7% in the neoadjuvant setting. In study E2301 40.2% of patients had de novo metastatic disease, 23.7% had bone-only disease, and 56.7% had visceral disease.
The study met the primary endpoint at the primary analysis conducted after 318 progression-free survival (PFS) events based on the investigator assessment using RECIST v1.1 criteria in the full analysis set (all randomised patients). The primary efficacy results were supported by PFS results based on blinded independent central radiological assessment. The median follow-up time at the time of primary PFS analysis was 19.2 months.

In the overall study population, the efficacy results demonstrated a statistically significant improvement in PFS in patients receiving Kisqali plus NSAI/tamoxifen plus goserelin compared to patients receiving placebo plus NSAI/tamoxifen plus goserelin (hazard ratio of 0.553, 95% CI: 0.441, 0.694, one-sided stratified log-rank test p-value 9.83x10^-8) with clinically meaningful treatment effect. Median PFS was 23.8 months (95% CI: 19.2, NE) for Kisqali plus NSAI/tamoxifen plus goserelin treated patients and 13.0 months (95% CI: 11.0, 16.4) for patients receiving placebo plus NSAI/tamoxifen plus goserelin.

Distribution of PFS is summarised in the Kaplan-Meier curve for PFS in Figure 3.

**Figure 3** MONALEESA-7 - Kaplan-Meier plot of PFS in overall population based on investigator assessment

The results for PFS based on the blinded independent central radiological assessment of a randomly selected subset of approximately 40% of randomised patients were supportive of the primary efficacy results based on the investigator’s assessment (hazard ratio of 0.427; 95% CI: 0.288, 0.633).

At the time of the primary PFS analysis overall survival data were not mature with 89 (13%) of deaths (HR 0.916 [95% CI: 0.601, 1.396]).

Overall response rate (ORR) per investigator assessment based on RECIST v1.1 was higher in the Kisqali arm (40.9%; 95% CI: 35.6, 46.2) compared to the placebo arm (29.7%; 95% CI: 24.8, 34.6, p=0.00098). The observed clinical benefit rate (CBR) was higher in Kisqali arm (79.1%; 95% CI: 74.8:83.5) compared to placebo arm (69.7%; 95% CI: 64.8:74.6, p=0.002).

In the pre-specified subgroup analysis of 495 patients who had received Kisqali or placebo in combination with NSAI plus goserelin, the median PFS was 27.5 months (95% CI: 19.1, NE) in the Kisqali plus NSAI subgroup and 13.8 months (95% CI: 12.6, 17.4) in the placebo plus NSAI subgroup [HR: 0.569; 95% CI: 0.436, 0.743]. Efficacy results are summarised in Table 11 and the Kaplan-Meier curves for PFS are provided in Figure 4.
Table 11  MONALEESA-7 - Efficacy results (PFS) in patients who received NSAI

<table>
<thead>
<tr>
<th></th>
<th>Kisqali plus NSAI plus goserelin</th>
<th>Placebo plus NSAI plus goserelin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=248</td>
<td>N=247</td>
</tr>
<tr>
<td><strong>Progression free survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median PFS [months] (95% CI)</td>
<td>27.5 (19.1, NE)</td>
<td>13.8 (12.6 – 17.4)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.569 (0.436, 0.743)</td>
<td></td>
</tr>
</tbody>
</table>

CI=confidence interval; N=number of patients; NE = Not estimable.

*PFS based on investigator radiological assessment

Figure 4  MONALEESA-7 – Kaplan-Meier plot of PFS based on investigator assessment in patients who received NSAI

Efficacy results for overall response rate (ORR) and clinical benefit rate (CBR) per investigator assessment based on RECIST v1.1 are provided in Table 12.

Table 12  MONALEESA-7 - Efficacy results (ORR, CBR) based on investigator assessment in patients who received NSAI

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Kisqali plus NSAI plus goserelin (%`, 95% CI)</th>
<th>Placebo plus NSAI plus goserelin (%`, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full analysis set</td>
<td>N=248</td>
<td>N=247</td>
</tr>
<tr>
<td>Overall response rate (ORR)*</td>
<td>39.1 (33.0, 45.2)</td>
<td>29.1 (23.5, 34.8)</td>
</tr>
<tr>
<td>Clinical benefit rate (CBR)*</td>
<td>80.2 (75.3, 85.2)</td>
<td>67.2 (61.4, 73.1)</td>
</tr>
<tr>
<td>Patients with measurable disease</td>
<td>n=192</td>
<td>n=199</td>
</tr>
<tr>
<td>Overall response rate*</td>
<td>50.5 (43.4, 57.6)</td>
<td>36.2 (29.5, 42.9)</td>
</tr>
<tr>
<td>Clinical benefit rate*</td>
<td>81.8 (76.3, 87.2)</td>
<td>63.8 (57.1, 70.5)</td>
</tr>
</tbody>
</table>

*ORR: proportion of patients with complete response + partial response

*CBR: proportion of patients with complete response + partial response + (stable disease or non-complete response/Non-progressive disease ≥24 weeks)
Results in the Kisqali plus NSAI subgroup were consistent across subgroups of age, race, prior adjuvant/ neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease.

A more mature update of overall survival data (30 November 2018 cut-off) is provided in Table 13 and Figures 5 and 6.

In the second OS analysis the study met its key secondary endpoint demonstrating a statistically significant improvement in OS.

Table 13  MONALEESA-7 – Efficacy results (OS) (30 November 2018 cut-off)

<table>
<thead>
<tr>
<th></th>
<th>Updated analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall survival, overall study population</strong></td>
<td></td>
</tr>
<tr>
<td>Kisqali 600 mg</td>
<td>Placebo</td>
</tr>
<tr>
<td>N=335</td>
<td>N=337</td>
</tr>
<tr>
<td>Number of events – n [%]</td>
<td>83 (24.8)</td>
</tr>
<tr>
<td>Median OS [months] (95% CI)</td>
<td>NE (NE, NE)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.712 (0.535, 0.948)</td>
</tr>
<tr>
<td>p-value*</td>
<td>0.00973</td>
</tr>
<tr>
<td><strong>Overall survival, NSAI subgroup</strong></td>
<td></td>
</tr>
<tr>
<td>Kisqali 600 mg</td>
<td>Placebo</td>
</tr>
<tr>
<td>n=248</td>
<td>n=247</td>
</tr>
<tr>
<td>Number of events – n [%]</td>
<td>61 (24.6)</td>
</tr>
<tr>
<td>Median OS [months] (95% CI)</td>
<td>NE (NE, NE)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.699 (0.501, 0.976)</td>
</tr>
</tbody>
</table>

CI=confidence interval, NE=not estimable, N=number of patients; *p-value is obtained from the one-sided log-rank test stratified by lung and/or liver metastases, prior chemotherapy for advanced disease, and endocrine combination partner per IRT (interactive response technology).

Figure 5  MONALEESA-7: Kaplan Meier plot of final OS analysis (30 November 2018 cut-off)

Log-rank test and Cox model are stratified by lung and/or liver metastases, prior chemotherapy for advanced disease, and endocrine combination partner per IRT.
Figure 6  MONALEESA-7: Kaplan Meier plot of final OS analysis in patients who received NSAIs (30 November 2018 cut-off)

Hazard ratio is based on unstratified Cox model.

Additionally, the probability of progression on next-line therapy or death (PFS2) in patients who received prior ribociclib in the study was lower compared to patients in the placebo arm with an HR of 0.692 (95% CI: 0.548, 0.875) in the overall study population. The median PFS2 was 32.3 months (95% CI: 27.6, 38.3) in the placebo arm and was not reached (95% CI: 39.4, NE) for the ribociclib arm. Similar results were observed for the NSAIs subgroup, with an HR of 0.660 (95% CI: 0.503, 0.868) and a median PFS2 of 32.3 months (95% CI: 26.9, 38.3) in the placebo arm versus not reached (95% CI: 39.4, NE) in the ribociclib arm.

Study CLEE011F2301 (MONALEESA-3)
Kisqali was evaluated in a 2:1 randomised double-blind, placebo-controlled, multicentre phase III clinical study in 726 postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who had received no or only one line of prior endocrine treatment, in combination with fulvestrant versus fulvestrant alone.

Patients enrolled in this study had a median age of 63 years (range 31 to 89). 46.7% of patients were of age 65 years and older, including 13.8% patients of age 75 years and older. The patients included were Caucasian (85.3%), Asian (8.7%) or Black (0.7%) and nearly all patients (99.7%) had an ECOG performance status of 0 or 1. First and second line patients were enrolled in this study (of whom 19.1% had de novo metastatic disease). Prior to study entry 42.7% of patients had received chemotherapy in the adjuvant and 13.1% in the neoadjuvant setting, while 58.5% had received endocrine therapy in the adjuvant and 1.4% in the neoadjuvant setting and 21% had received prior endocrine therapy in the advanced breast cancer setting. In study F2301 21.2% had bone-only disease and 60.5% had visceral disease.
Primary analysis
The study met the primary endpoint at the primary analysis conducted after 361 progression-free survival (PFS) events based on the investigator assessment and using RECIST v1.1 criteria in the full analysis set (all randomised patients, 03 November 2017 cut-off). The median follow-up time at the time of primary PFS analysis was 20.4 months.

The primary efficacy results demonstrated a statistically significant improvement in PFS in patients receiving Kisqali plus fulvestrant compared to patients receiving placebo plus fulvestrant in the full analysis set (hazard ratio of 0.593, 95% CI: 0.480, 0.732, one-sided stratified log-rank test p-value 4.1x10^{-7}), with an estimated 41% reduction in relative risk of progression or death in favour of the Kisqali plus fulvestrant arm.

The primary efficacy results were supported by a random central audit of 40% imaging subset by a blinded independent central radiological assessment (hazard ratio of 0.492; 95% CI: 0.345, 0.703).

A descriptive update of PFS was performed at the time of the second OS interim analysis, and the updated PFS results on the overall population and the subgroups based on prior endocrine therapy are summarised in Table 14 and the Kaplan-Meier curve is provided in Figure 7.

Table 14 MONALEESA-3 (F2301) - Updated PFS results based on investigator assessment (03 June 2019 cut-off)

<table>
<thead>
<tr>
<th>Progression free survival overall study population</th>
<th>Kisqali plus fulvestrant N=484</th>
<th>Placebo plus fulvestrant N=242</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of events- n [%]</td>
<td>283 (58.5)</td>
<td>193 (79.8)</td>
</tr>
<tr>
<td>Median PFS [months] (95% CI)</td>
<td>20.6 (18.6, 24.0)</td>
<td>12.8 (10.9, 16.3)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.587 (0.488, 0.705)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>First-line setting subgroup*</th>
<th>Kisqali plus fulvestrant n=237</th>
<th>Placebo plus fulvestrant n=128</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of events- n [%]</td>
<td>112 (47.3)</td>
<td>95 (74.2)</td>
</tr>
<tr>
<td>Median PFS [months] (95% CI)</td>
<td>33.6 (27.1, 41.3)</td>
<td>19.2 (14.9, 23.6)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.546 (0.415, 0.718)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second-line setting or early relapse subgroupb</th>
<th>Kisqali plus fulvestrant n=237</th>
<th>Placebo plus fulvestrant n=109</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of events- n [%]</td>
<td>167 (70.5)</td>
<td>95 (87.2)</td>
</tr>
<tr>
<td>Median PFS [months] (95% CI)</td>
<td>14.6 (12.5, 18.6)</td>
<td>9.1 (5.8, 11.0)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.571 (0.443, 0.737)</td>
<td></td>
</tr>
</tbody>
</table>

CI=confidence interval

* patients with de novo advanced breast cancer with no prior endocrine therapy, and patients who relapsed after 12 months of (neo)adjuvant endocrine therapy completion.

b patients whose disease relapsed during adjuvant therapy or within 12 months of (neo)adjuvant endocrine therapy completion, and patients who had progression after one line of endocrine therapy for advanced disease.
Efficacy results for overall response rate (ORR) and clinical benefit rate (CBR) per investigator assessment based on RECIST v1.1 are provided in Table 15.

Table 15  MONALEESA-3 - Efficacy results (ORR, CBR) based on investigator assessment (03 November 2017 cut-off)

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Kisqali plus fulvestrant (%, 95% CI)</th>
<th>Placebo plus fulvestrant (%, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full analysis set</td>
<td>N=484</td>
<td>N=242</td>
</tr>
<tr>
<td>Overall response rate (ORR)a</td>
<td>32.4 (28.3, 36.6)</td>
<td>21.5 (16.3, 26.7)</td>
</tr>
<tr>
<td>Clinical benefit rate (CBR)b</td>
<td>70.2 (66.2, 74.3)</td>
<td>62.8 (56.7, 68.9)</td>
</tr>
<tr>
<td>Patients with measurable disease n=379</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall response ratea</td>
<td>40.9 (35.9, 45.8)</td>
<td>28.7 (22.1, 35.3)</td>
</tr>
<tr>
<td>Clinical benefit rateb</td>
<td>69.4 (64.8, 74.0)</td>
<td>59.7 (52.5, 66.8)</td>
</tr>
</tbody>
</table>

a ORR: proportion of patients with complete response + partial response
b CBR: proportion of patients with complete response + partial response + (stable disease or non-complete response/Non-progressive disease ≥24 weeks)

Hazard ratios based on pre-specified subgroup analysis of the patients treated with Kisqali plus fulvestrant showed consistent benefit across different subgroups including age, prior treatment (early or advanced), prior adjuvant/neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement and bone-only metastatic disease.

OS Analysis
In the second OS analysis the study met its secondary endpoint, demonstrating a statistically significant improvement in OS.

The results from this final OS analysis on the overall study population and the subgroups analysis are provided in Table 16 and Figure 8.
Table 16  MONALEESA-3 (F2301) efficacy results (OS) (03 June 2019 cut-off)

<table>
<thead>
<tr>
<th>Overall study population</th>
<th>Kisqali plus fulvestrant</th>
<th>Placebo plus fulvestrant</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=484</td>
<td>N=242</td>
<td></td>
</tr>
<tr>
<td>Median OS [months] (95% CI)</td>
<td>167 (34.5)</td>
<td>108 (44.6)</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.724 (0.568, 0.924)</td>
<td></td>
</tr>
<tr>
<td>p value</td>
<td>0.00455</td>
<td></td>
</tr>
<tr>
<td>First line setting subgroup</td>
<td>n=237</td>
<td>n=128</td>
</tr>
<tr>
<td>Number of events - n [%]</td>
<td>63 (26.6)</td>
<td>47 (36.7)</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.700 (0.479, 1.021)</td>
<td></td>
</tr>
<tr>
<td>Second-line setting or early relapse subgroup</td>
<td>n=237</td>
<td>n=109</td>
</tr>
<tr>
<td>Number of events - n [%]</td>
<td>102 (43.0)</td>
<td>60 (55.0)</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.730 (0.530, 1.004)</td>
<td></td>
</tr>
</tbody>
</table>

NE=Not estimable

a Hazard ratio is obtained from the Cox PH model stratified by lung and/or liver metastasis, previous endocrine therapy.

b One-sided P-value is obtained from log-rank test stratified by lung and/or liver metastasis, previous endocrine therapy per IRT. P-value is one-sided and is compared against a threshold of 0.01129 as determined by the Lan-DeMets (O'Brien-Fleming) alpha-spending function for an overall significance level of 0.025.

c Hazard ratio is obtained from the unstratified Cox PH model.

Figure 8  MONALEESA-3 (F2301) Kaplan-Meier plot of OS (full analysis set [FAS]) (03 June 2019 cut-off)

Log-rank test and Cox model are stratified by lung and/or liver metastasis, prior chemotherapy for advanced disease, and endocrine combination partner per IRT

Time to progression on next-line therapy or death (PFS2) in patients in the Kisqali arm was longer compared to patients in the placebo arm (HR: 0.670 [95% CI: 0.542, 0.830]) in the overall study population. The median PFS2 was 39.8 months (95% CI: 32.5, NE) for the Kisqali arm and 29.4 months (95% CI: 24.1, 33.1) in the placebo arm.
**Elderly patients**
Of all patients who received Kisqali in studies MONALEESA-2 and MONALEESA-3, representative proportions of patients were ≥65 years and ≥75 years of age (see section 5.1). No overall differences in safety or effectiveness of Kisqali were observed between these patients and younger patients (see section 4.2).

**Patients with renal impairment**
In the three pivotal studies (MONALEESA-2, MONALEESA-3 and MONALEESA-7), 510 (53.8%) patients with normal renal function, 341 (36%) patients with mild renal impairment and 97 (10.2%) patients with moderate renal impairment were treated with ribociclib. No patient with severe renal impairment was enrolled. PFS results were consistent in patients with mild and moderate renal impairment who received ribociclib at the starting dose of 600 mg as compared to those with normal renal function. The safety profile was generally consistent across renal cohorts (see section 4.8).

**Paediatric population**
The European Medicines Agency has waived the obligation to submit the results of studies with Kisqali in all subsets of the paediatric population in breast cancer (see section 4.2 for information on paediatric use).

### 5.2 Pharmacokinetic properties

The pharmacokinetics of ribociclib were investigated in patients with advanced cancer following oral daily doses of 50 mg to 1200 mg. Healthy subjects received single oral doses ranging from 400 mg to 600 mg or repeated daily doses (8 days) at 400 mg.

**Absorption**

The absolute bioavailability of ribociclib is not known.

The time to reach $C_{\text{max}}$ ($T_{\text{max}}$) following ribociclib oral administration was between 1 and 4 hours. Ribociclib exhibited slightly over-proportional increases in exposure ($C_{\text{max}}$ and AUC) across the dose range tested (50 to 1200 mg). Following repeated once-daily dosing, steady state was generally achieved after 8 days and ribociclib accumulated with a geometric mean accumulation ratio of 2.51 (range: 0.97 to 6.40).

**Food effect**

Compared to the fasted state, oral administration of a single 600 mg dose of ribociclib film-coated tablets with a high-fat, high-calorie meal had no effect on the rate and extent of absorption of ribociclib.

**Distribution**

Binding of ribociclib to human plasma proteins *in vitro* was approximately 70% and was independent of concentration (10 to 10000 ng/ml). Ribociclib was equally distributed between red blood cells and plasma with a mean *in vivo* blood-to-plasma ratio of 1.04. The apparent volume of distribution at steady state (Vss/F) was 1090 L based on population pharmacokinetic analysis.
Biotransformation

*In vitro* and *in vivo* studies indicated ribociclib is eliminated primarily via hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a single 600 mg dose of 

\[ ^{14}C \] ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation (dealkylation, C and/or N-oxygenation, oxidation (-2H)) and combinations thereof. Phase II conjugates of ribociclib phase I metabolites involved N-acetylation, sulfation, cysteine conjugation, glycosylation and glucuronidation. Ribociclib was the major circulating drug-derived entity in plasma. The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide). Clinical activity (pharmacological and safety) of ribociclib was due primarily to parent drug, with negligible contribution from circulating metabolites.

Ribociclib was extensively metabolised, with unchanged drug accounting for 17.3% and 12.1% of the dose in faeces and urine, respectively. Metabolite LEQ803 was a significant metabolite in excreta and represented approximately 13.9% and 3.74% of the administered dose in faeces and urine, respectively. Numerous other metabolites were detected in both faeces and urine in minor amounts (≤2.78% of the administered dose).

**Elimination**

The geometric mean plasma effective half-life (based on accumulation ratio) was 32.0 hours (63% CV) and the geometric mean apparent oral clearance (CL/F) was 25.5 l/hr (66% CV) at steady state at 600 mg in patients with advanced cancer. The geometric mean apparent plasma terminal half-life (T\(_{1/2}\)) of ribociclib ranged from 29.7 to 54.7 hours and the geometric mean CL/F of ribociclib ranged from 39.9 to 77.5 l/hr at 600 mg across studies in healthy subjects.

Ribociclib and its metabolites are eliminated mainly via faeces, with a small contribution of the renal route. In 6 healthy male subjects, following a single oral dose of 

\[ ^{14}C \] ribociclib, 91.7% of the total administered radioactive dose was recovered within 22 days; faeces was the major route of excretion (69.1%), with 22.6% of the dose recovered in urine.

**Linearity/non-linearity**

Ribociclib exhibited slightly over-proportional increases in exposure (C\(_{\text{max}}\) and AUC) across the dose range of 50 mg to 1200 mg following both single dose and repeated doses. This analysis is limited by the small sample sizes for most of the dose cohorts with a majority of the data coming from the 600 mg dose cohort.

**Special populations**

**Renal impairment**

The effect of renal function on the pharmacokinetics of ribociclib was assessed in a renal impairment study that included 14 healthy subjects with normal renal function (absolute Glomerular Filtration Rate [aGFR] ≥90 ml/min), 8 subjects with mild renal impairment (aGFR 60 to <90 ml/min), 6 subjects with moderate renal impairment (aGFR 30 to <60 ml/min), 7 subjects with severe renal impairment (aGFR 15 to <30 ml/min) and 3 subjects with end-stage renal disease (ESRD) (aGFR <15 ml/min) at a single ribociclib dose of 400 mg.

AUC\(_{\text{inf}}\) increased 1.6-fold, 1.9-fold and 2.7-fold and C\(_{\text{max}}\) increased 1.8-fold, 1.8-fold and 2.3-fold in subjects with mild, moderate and severe renal impairment relative to the exposure in subjects with normal renal function. Since the efficacy and safety studies of ribociclib included a large proportion of patients with mild renal impairment (see section 5.1), data from the subjects with moderate or severe renal impairment in the renal impairment study were also compared with pooled data for the subjects with normal renal function and mild renal impairment. Compared to the pooled data for the subjects with normal renal function and mild renal impairment, AUC\(_{\text{inf}}\) increased 1.6-fold and 2.2-fold and C\(_{\text{max}}\) increased 1.5-fold and 1.9-fold in subjects with moderate and severe renal impairment, respectively. A fold difference for subjects with ESRD was not calculated due to the small number of subjects, but
results indicate a similar or somewhat larger increase in ribociclib exposure compared to subjects with severe renal impairment.

The effect of renal function on the pharmacokinetics of ribociclib was also assessed in cancer patients included in efficacy and safety studies where patients were given the 600 mg start dose (see section 5.1). In a sub-group analysis of pharmacokinetic data from studies in cancer patients following oral administration of 600 mg ribociclib as a single dose or repeat doses, AUC_{inf} and C_{max} of ribociclib in patients with mild (n=57) or moderate (n=14) renal impairment were comparable to the AUC_{inf} and C_{max} in patients with normal renal function (n=86), suggesting no clinically meaningful effect of mild or moderate renal impairment on ribociclib exposure.

**Hepatic impairment**

Based on a pharmacokinetic study in non-cancer subjects with hepatic impairment, mild hepatic impairment had no effect on the exposure of ribociclib (see section 4.2). The mean exposure for ribociclib was increased less than 2-fold in patients with moderate (geometric mean ratio [GMR]: 1.44 for C_{max}; 1.28 for AUC_{inf}) and severe (GMR: 1.32 for C_{max}; 1.29 for AUC_{inf}) hepatic impairment (see section 4.2).

Based on a population pharmacokinetic analysis that included 160 breast cancer patients with normal hepatic function and 47 patients with mild hepatic impairment, mild hepatic impairment had no effect on the exposure of ribociclib, further supporting the findings from the dedicated hepatic impairment study. Ribociclib has not been studied in breast cancer patients with moderate or severe hepatic impairment.

**Effect of age, weight, gender and race**

Population pharmacokinetic analysis showed that there are no clinically relevant effects of age, body weight or gender on the systemic exposure of ribociclib that would require a dose adjustment. Data on differences in pharmacokinetics due to race are too limited to draw conclusions.

**In vitro interaction data**

**Effect of ribociclib on cytochrome P450 enzymes**

*In vitro*, ribociclib is a reversible inhibitor of CYP1A2, CYP2E1 and CYP3A4/5 and a time-dependent inhibitor of CYP3A4/5, at clinically relevant concentrations. *In vitro* evaluations indicated that ribociclib has no potential to inhibit the activities of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 at clinically relevant concentrations. Ribociclib has no potential for time-dependent inhibition of CYP1A2, CYP2C9, and CYP2D6.

*In vitro* data indicate that ribociclib has no potential to induce UGT enzymes or the CYP enzymes CYP2C9, CYP2C19 and CYP3A4 via PXR. Therefore, Kisqali is unlikely to affect substrates of these enzymes. *In vitro* data are not sufficient to exclude a potential of ribociclib to induce CYP2B6 via CAR.

**Effect of transporters on ribociclib**

Ribociclib is a substrate for P-gp *in vitro*, but based on mass balance data inhibition of P-gp or BCRP is unlikely to affect ribociclib exposure at therapeutic doses. Ribociclib is not a substrate for hepatic uptake transporters OATP1B1, OATP1B3 or OCT-1 *in vitro*.

**Effect of ribociclib on transporters**

*In vitro* evaluations indicated that ribociclib has a potential to inhibit the activities of drug transporters P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 and BSEP. Ribociclib did not inhibit OAT1, OAT3 or MRP2 at clinically relevant concentrations *in vitro*.
5.3 Preclinical safety data

Safety pharmacology

*In vivo* cardiac safety studies in dogs demonstrated dose and concentration related QTc interval prolongation at an exposure that would be expected to be achieved in patients following the recommended dose of 600 mg. There is also potential to induce incidences of premature ventricular contractions (PVCs) at elevated exposures (approximately 5-fold the anticipated clinical $C_{\text{max}}$).

Repeated-dose toxicity

Repeated-dose toxicity studies (treatment schedule of 3 weeks on/1 week off) of up to 27 weeks’ duration in rats and up to 39 weeks’ duration in dogs, revealed the hepatobiliary system (proliferative changes, cholestasis, sand-like gallbladder calculi, and inspissated bile) as the primary target organ of toxicity of ribociclib. Target organs associated with the pharmacological action of ribociclib in repeat-dose studies include bone marrow (hypocellularity), lymphoid system (lymphoid depletion), intestinal mucosa (atrophy), skin (atrophy), bone (decreased bone formation), kidney (concurrent degeneration and regeneration of tubular epithelial cells) and testes (atrophy). Besides the atrophic changes seen in the testes, which showed a trend towards reversibility, all other changes were fully reversible after a 4-week treatment-free period. Exposure to ribociclib in animals in the toxicity studies was generally less than or equal to that observed in patients receiving multiple doses of 600 mg/day (based on AUC).

Reproductive toxicity/Fertility

Ribociclib showed foetotoxicity and teratogenicity at doses which did not show maternal toxicity in the rats or rabbits. Following prenatal exposure, increased incidences of post-implantation loss and reduced foetal weights were observed in rats and ribociclib was teratogenic in rabbits at exposures lower than or 1.5 times the exposure in humans, respectively, at the highest recommended dose of 600 mg/day based on AUC.

In rats, reduced foetal weights accompanied by skeletal changes considered to be transitory and/or related to the lower foetal weights were noted. In rabbits, there were adverse effects on embryo-foetal development as evidenced by increased incidences of foetal abnormalities (malformations and external, visceral and skeletal variants) and foetal growth (lower foetal weights). These findings included reduced/small lung lobes and additional vessel on the aortic arch and diaphragmatic hernia, absent accessory lobe or (partly) fused lung lobes and reduced/small accessory lung lobe (30 and 60 mg/kg), extra/rudimentary thirteenth ribs and misshapen hyoid bone and reduced number of phalanges in the pollex. There was no evidence of embryo-foetal mortality.

In a fertility study in female rats, ribociclib did not affect reproductive function, fertility or early embryonic development at any dose up to 300 mg/kg/day (which is likely at an exposure lower than or equal to patients’ clinical exposure at the highest recommended dose of 600 mg/day based on AUC).

Ribociclib has not been evaluated in male fertility studies. However, atrophic changes in testes were reported in rat and dog toxicity studies at exposures that were less than or equal to human exposure at the highest recommended daily dose of 600 mg/day based on AUC. These effects can be linked to a direct anti-proliferative effects on the testicular germ cells resulting in atrophy of the seminiferous tubules.

Ribociclib and its metabolites passed readily into rat milk. The exposure to ribociclib was higher in milk than in plasma.

Genotoxicity

Genotoxicity studies in bacterial *in vitro* systems and in mammalian *in vitro* and *in vivo* systems with and without metabolic activation did not reveal any evidence for a genotoxic potential of ribociclib.
Carcinogenesis

Ribociclib was assessed for carcinogenicity in a 2-year study in rats.

Oral administration of ribociclib for 2 years resulted in an increased incidence of endometrial epithelial tumours and glandular and squamous hyperplasia in the uterus/cervix of female rats at doses ≥300 mg/kg/day as well as an increased incidence in follicular tumours in the thyroid glands of male rats at a dose of 50 mg/kg/day. Mean exposure at steady state (AUC<sub>0-24h</sub>) in female and male rats in whom neoplastic changes were seen was 1.2- and 1.4-fold that achieved in patients at the recommended dose of 600 mg/day, respectively. Mean exposure at steady state (AUC<sub>0-24h</sub>) in female and male rats in whom neoplastic changes were seen was 2.2- and 2.5-fold that achieved in patients at a dose of 400 mg/day, respectively.

Additional non-neoplastic proliferative changes consisted of increased liver altered foci (basophilic and clear cell) and testicular interstitial (Leydig) cell hyperplasia in male rats at doses of ≥5 mg/kg/day and 50 mg/kg/day, respectively.

The effects on the uterus/cervix and on the testicular interstitial (Leydig) cells may be related to prolonged hypoprolactinemia secondary to CDK4 inhibition of lactotrophic cell function in the pituitary gland, altering the hypothalamus-pituitary-gonadal axis.

Potential mechanisms for the thyroid findings in males include a rodent-specific microsomal enzyme induction in the liver and/or a dysregulation of the hypothalamus-pituitary-testis-thyroid axis secondary to a persistent on-target hypoprolactinemia.

Any potential increase of oestrogen/progesterone ratio in humans by this mechanism would be compensated by an inhibitory action of concomitant anti-oestrogen therapy on oestrogen synthesis as in humans Kisqali is indicated in combination with oestrogen-lowering agents.

Considering important differences between rodents and humans with regard to synthesis and role of prolactin, this mode of action is not expected to have consequences in humans.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core

- Microcrystalline cellulose
- Crospovidone type A
- Low-substituted hydroxypropylcellulose
- Magnesium stearate
- Colloidal anhydrous silica

Film coating

- Iron oxide black (E172)
- Iron oxide red (E172)
- Soya lecithin (E322)
- Polyvinyl alcohol (partially hydrolysed)
- Talc
- Titanium dioxide (E171)
- Xanthan gum
6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/PCTFE (polyvinylchloride/polychlorotrifluoroethylene) or PA/alu/PVC (polyamide/aluminium/polyvinylchloride) blisters containing 14 or 21 film-coated tablets.

Unit packs containing 21, 42 or 63 film-coated tablets and multipacks containing 63 (3 packs of 21), 126 (3 packs of 42) or 189 (3 packs of 63) film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1221/001-012

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 22 August 2017
Date of latest renewal: 04 April 2022

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Kisqali 200 mg film-coated tablets
ribociclib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains ribociclib succinate, equivalent to 200 mg ribociclib.

3. LIST OF EXCIPIENTS

Contains soya lecithin. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablet

21 film-coated tablets
42 film-coated tablets
63 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.
Enter weekdays starting with the 1st day of treatment. Mark off circle for every tablet you take.
Take your dose once a day for 3 weeks followed by a 1-week break.
No Kisqali this week.
Day
Week

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

- EU/1/17/1221/001: 21 film-coated tablets (in PCTFE/PVC blisters)
- EU/1/17/1221/002: 21 film-coated tablets (in PA/alu/PVC blisters)
- EU/1/17/1221/003: 42 film-coated tablets (in PCTFE/PVC blisters)
- EU/1/17/1221/004: 42 film-coated tablets (in PA/alu/PVC blisters)
- EU/1/17/1221/005: 63 film-coated tablets (in PCTFE/PVC blisters)
- EU/1/17/1221/006: 63 film-coated tablets (in PA/alu/PVC blisters)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Kisqali 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
<th>OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. <strong>NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
</tr>
<tr>
<td>Kisqali 200 mg film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>ribociclib</td>
<td></td>
</tr>
<tr>
<td>2. <strong>STATEMENT OF ACTIVE SUBSTANCE(S)</strong></td>
<td></td>
</tr>
<tr>
<td>Each film-coated tablet contains ribociclib</td>
<td></td>
</tr>
<tr>
<td>succinate, equivalent to 200 mg ribociclib.</td>
<td></td>
</tr>
<tr>
<td>3. <strong>LIST OF EXCIPIENTS</strong></td>
<td></td>
</tr>
<tr>
<td>Contains soya lecithin. See leaflet for</td>
<td></td>
</tr>
<tr>
<td>further information.</td>
<td></td>
</tr>
<tr>
<td>4. <strong>PHARMACEUTICAL FORM AND CONTENTS</strong></td>
<td></td>
</tr>
<tr>
<td>Film-coated tablet</td>
<td></td>
</tr>
<tr>
<td>Multipack: 63 (3 packs of 21) film-coated</td>
<td></td>
</tr>
<tr>
<td>tablets</td>
<td></td>
</tr>
<tr>
<td>Multipack: 126 (3 packs of 42) film-coated</td>
<td></td>
</tr>
<tr>
<td>tablets</td>
<td></td>
</tr>
<tr>
<td>Multipack: 189 (3 packs of 63) film-coated</td>
<td></td>
</tr>
<tr>
<td>tablets</td>
<td></td>
</tr>
<tr>
<td>5. <strong>METHOD AND ROUTE(S) OF ADMINISTRATION</strong></td>
<td></td>
</tr>
<tr>
<td>Oral use</td>
<td></td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
<td></td>
</tr>
<tr>
<td>6. **SPECIAL WARNING THAT THE MEDICINAL</td>
<td></td>
</tr>
<tr>
<td>PRODUCT MUST BE STORED OUT OF THE SIGHT AND</td>
<td></td>
</tr>
<tr>
<td>REACH OF CHILDREN</td>
<td></td>
</tr>
<tr>
<td>Keep out of the sight and reach of children.</td>
<td></td>
</tr>
<tr>
<td>7. <strong>OTHER SPECIAL WARNING(S), IF NECESSARY</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>8. <strong>EXPIRY DATE</strong></td>
<td></td>
</tr>
<tr>
<td>EXP</td>
<td></td>
</tr>
<tr>
<td>9. <strong>SPECIAL STORAGE CONDITIONS</strong></td>
<td></td>
</tr>
</tbody>
</table>
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/17/1221/007</td>
<td>63 (3 x 21) film-coated tablets (in PCTFE/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/008</td>
<td>63 (3 x 21) film-coated tablets (in PA/alu/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/009</td>
<td>126 (3 x 42) film-coated tablets (in PCTFE/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/010</td>
<td>126 (3 x 42) film-coated tablets (in PA/alu/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/011</td>
<td>189 (3 x 63) film-coated tablets (in PCTFE/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/012</td>
<td>189 (3 x 63) film-coated tablets (in PA/alu/PVC blisters)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Kisqali 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
## PARTICULARS TO APPEAR ON THE OUTER PACKAGING

### INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kisqali 200 mg film-coated tablets</td>
</tr>
<tr>
<td>ribociclib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each film-coated tablet contains ribociclib succinate, equivalent to 200 mg ribociclib.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contains soya lecithin. See leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Film-coated tablet</td>
</tr>
<tr>
<td>21 film-coated tablets. Component of a multipack. Not to be sold separately.</td>
</tr>
<tr>
<td>42 film-coated tablets. Component of a multipack. Not to be sold separately.</td>
</tr>
<tr>
<td>63 film-coated tablets. Component of a multipack. Not to be sold separately.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral use</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Enter weekdays starting with the 1st day of treatment. Mark off circle for every tablet you take.</td>
</tr>
<tr>
<td>Take your dose once a day for 3 weeks followed by a 1-week break.</td>
</tr>
<tr>
<td>No Kisqali this week.</td>
</tr>
<tr>
<td>Day</td>
</tr>
<tr>
<td>Week</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>
9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Marketing Authorisation Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/17/1221/007</td>
<td>63 (3 x 21) film-coated tablets (in PCTFE/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/008</td>
<td>63 (3 x 21) film-coated tablets (in PA/alu/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/009</td>
<td>126 (3 x 42) film-coated tablets (in PCTFE/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/010</td>
<td>126 (3 x 42) film-coated tablets (in PA/alu/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/011</td>
<td>189 (3 x 63) film-coated tablets (in PCTFE/PVC blisters)</td>
</tr>
<tr>
<td>EU/1/17/1221/012</td>
<td>189 (3 x 63) film-coated tablets (in PA/alu/PVC blisters)</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Kisqali 200 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLISTERS</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. <strong>NAME OF THE MEDICINAL PRODUCT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kisqali 200 mg film-coated tablets</td>
</tr>
<tr>
<td>ribociclib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. <strong>NAME OF THE MARKETING AUTHORIZATION HOLDER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Europharm Limited</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. <strong>EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. <strong>BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. <strong>OTHER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
</tr>
<tr>
<td>Tuesday</td>
</tr>
<tr>
<td>Wednesday</td>
</tr>
<tr>
<td>Thursday</td>
</tr>
<tr>
<td>Friday</td>
</tr>
<tr>
<td>Saturday</td>
</tr>
<tr>
<td>Sunday</td>
</tr>
</tbody>
</table>
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Kisqali 200 mg film-coated tablets
ribociclib

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Kisqali is and what it is used for
2. What you need to know before you take Kisqali
3. How to take Kisqali
4. Possible side effects
5. How to store Kisqali
6. Contents of the pack and other information

1. What Kisqali is and what it is used for

What Kisqali is
Kisqali contains the active substance ribociclib, which belongs to a group of medicines called cyclin-dependent kinase (CDK) inhibitors.

What Kisqali is used for
Kisqali is used in women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor (HER2)-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic). It is used in combination with an aromatase inhibitor or fulvestrant, which are used as hormonal anticancer therapies.

Women who have not reached menopause will also be treated with a medicine called a luteinising hormone releasing hormone (LHRH) agonist.

How Kisqali works
Kisqali works by blocking proteins called cyclin-dependent kinases 4 and 6, which are important for the growth and division of cells. Blocking these proteins can slow down the growth of cancer cells and delay the progression of your cancer.

If you have any questions about how Kisqali works or why this medicine has been prescribed for you, ask your doctor, pharmacist or nurse.
2. **What you need to know before you take Kisqali**

Follow all of your doctor’s instructions carefully. They may differ from the general information in this leaflet.

**Do not take Kisqali**
- if you are allergic to ribociclib, peanut, soya or any of the other ingredients of this medicine (listed in section 6).

If you think you may be allergic, ask your doctor for advice.

**Warnings and precautions**
Talk to your doctor, pharmacist or nurse before taking Kisqali.

**If any of the following apply to you before taking Kisqali, tell your doctor or pharmacist:**
- If you have a fever, sore throat or mouth ulcers due to infections (signs of a low level of white blood cells).
- If you have any problems with your liver or have previously had any type of liver disease.
- If you have or have had heart disorders or heart rhythm disorders, such as an irregular heartbeat, including a condition called prolonged QT syndrome (QT interval prolongation) or low levels of potassium, magnesium, calcium or phosphorus in your blood.

**If any of the following apply to you during your treatment with Kisqali, tell your doctor or pharmacist:**
- If you have a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms and enlarged lymph nodes (signs of a severe skin reaction).
  In case of a severe skin reaction, your doctor will ask you to immediately stop treatment with Kisqali.
- Trouble breathing, cough and shortness of breath (may be signs of lung or breathing problems).
  If necessary, your doctor may interrupt or reduce your dose of Kisqali or decide to stop treatment with Kisqali permanently.

**Monitoring during your treatment with Kisqali**
You will have regular blood tests before and during treatment with Kisqali to check your liver function and the amount of blood cells (white blood cells, red blood cells and platelets) and electrolytes (blood salts including potassium, calcium, magnesium and phosphate) in your body. Your heart activity will also be monitored before and during treatment with Kisqali with a test called an electrocardiogram (ECG). If necessary, additional tests to evaluate your kidney function will be performed during treatment with Kisqali. If necessary, your doctor may reduce your dose of Kisqali or temporarily stop it to allow your liver, kidney, blood cells, electrolyte levels or heart activity to recover. Your doctor may also decide to stop treatment with Kisqali permanently.

**Children and adolescents**
Kisqali is not to be used in children and adolescents under 18 years of age.
Other medicines and Kisqali
Before you take Kisqali, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines or supplements obtained without a prescription, because these may influence the effect of Kisqali. This includes in particular:

- Tamoxifen, another medicine for the treatment of breast cancer.
- Some medicines used to treat fungal infections, such as ketoconazole, itraconazole, voriconazole or posaconazole.
- Some medicines used to treat HIV/AIDS such as ritonavir, saquinavir, indinavir, lopinavir, nelfinavir, telaprevir and efavirenz.
- Some medicines used to treat seizures or fits (anti-epileptics) such as carbamazepine and phenytoin.
- St. John’s Wort (also known as Hypericum perforatum) - a herbal product used to treat depression and other conditions.
- Some medicines used to treat heart rhythm problems or high blood pressure such as amiodarone, disopyramide, procainamide, quinidine, sotalol and verapamil.
- Antimalarials such as chloroquine.
- Antibiotics such as clarithromycin, telithromycin, moxifloxacin, rifampicin, ciprofloxacin, levofloxacin and azithromycin.
- Some medicines used for sedation or anaesthesia such as midazolam.
- Some medicines used as antipsychotics such as haloperidol.
- Medicines used to treat angina such as bepridil.
- Methadone, used to treat pain or addiction to opioids.
- Medicines like intravenous ondansetron, used to prevent nausea and vomiting caused by chemotherapy (treatment with cancer medicines).

Kisqali may increase or decrease your blood levels of some other medicines. This includes in particular:

- Medicines used to treat symptoms of benign prostatic hyperplasia such as alfuzosin.
- Tamoxifen, another medicine used for the treatment of breast cancer.
- Antiarrhythmics such as amiodarone or quinidine.
- Antipsychotics such as pimozide or quetiapine.
- Medicines used to improve blood fat levels such as simvastatin or lovastatin, pitavastatin, pravastatin or rosuvastatin.
- Medicines used to treat high blood sugar levels (e.g. diabetes) such as metformin.
- Medicines used to treat cardiac disorders such as digoxin
- Medicines used to treat pulmonary arterial hypertension and erectile dysfunction such as sildenafil.
- Medicines used to treat low blood pressure or migraine such as ergotamine or dihydroergotamine.
- Some medicines used to treat epileptic fits or which are used for sedation or anaesthesia such as midazolam.
- Medicines used to treat sleep disorders such as triazolam.
- Analgesics such as alfentanil and fentanyl.
- Medicines used for the treatment of gastrointestinal disorders such as cisapride.
- Medicines used to prevent the rejection of an organ transplant such as tacrolimus, sirolimus and ciclosporin (also used to treat inflammation in rheumatoid arthritis and psoriasis).
- Everolimus, used for several types of cancer and tuberous sclerosis (also used to prevent the rejection of an organ transplant).
Make sure you tell your doctor of all medicines and supplements, including herbal medicines, that you are taking before you start treatment with Kisqali and if you are prescribed a new medicine after you have started treatment with Kisqali.

Ask your doctor or pharmacist if you are not sure if your medicine is one of the medicines listed above.

**Kisqali with food and drink**

**You should not eat grapefruits or drink grapefruit juice** during your treatment with Kisqali. It may change how Kisqali is processed in your body and may increase the amount of Kisqali in your bloodstream.

**Pregnancy and breast-feeding**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Your doctor will discuss with you the potential risks of taking Kisqali during pregnancy.

**Pregnancy and women of childbearing potential**

Kisqali should not be used during pregnancy since it may harm your unborn baby. If you are a woman of childbearing potential you should have a negative pregnancy test before starting treatment with Kisqali. You should use effective contraception (e.g. double-barrier contraception such as condom and diaphragm) while taking Kisqali and for at least 21 days after the last dose. Ask your doctor about options for effective contraception.

**Breast-feeding**

You should not breast-feed while taking Kisqali and for at least 21 days after the last dose.

**Driving and using machines**

Treatment with Kisqali may lead to tiredness, dizziness or spinning sensation. You should therefore be cautious when driving or using machines during your treatment with Kisqali.

**Kisqali contains soya lecithin**

If you are allergic to peanut or soya, do not use this medicine.
3. **How to take Kisqali**

Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Your doctor, pharmacist or nurse will tell you exactly how many tablets to take and which days to take them on. Check with your doctor, pharmacist or nurse if you are not sure. Do not change the Kisqali dose or schedule without talking to your doctor.

Do not exceed the recommended dose prescribed by your doctor.

**How much Kisqali to take**

- The recommended starting dose of Kisqali is 600 mg (3 tablets of 200 mg) once daily. Your doctor will tell you exactly how many tablets of Kisqali to take; in certain situations (e.g. in case of liver or kidney problems) your doctor may instruct you to take a lower dose of Kisqali, e.g. 400 mg (2 tablets of 200 mg) once daily or 200 mg (1 tablet of 200 mg) once daily.
- A treatment cycle lasts 28 days. Take Kisqali once a day only on days 1 to 21 of a 28-day cycle. The outer carton of the Kisqali pack includes a “calendar tool” which allows you to track your daily Kisqali dose by marking off a circle for every tablet you take over the 28-day cycle. You should not take Kisqali on days 22 to 28 of the cycle.

It is very important to follow your doctor’s instructions. If you get certain side effects your doctor may ask you to take a lower dose, interrupt your treatment with Kisqali, or stop it permanently.

**When to take Kisqali**

Take Kisqali once daily at the same time each day, preferably in the morning. This will help you to remember to take your medicine.

**How to take Kisqali**

Kisqali tablets should be swallowed whole (tablets should not be chewed, crushed or split before swallowing). Do not take a tablet that is broken, cracked or otherwise damaged.

**Kisqali with food and drink**

You should take Kisqali once daily every day at the same time, preferably in the morning. You may take it with or without food.

**How long to take Kisqali**

Take Kisqali once a day on days 1 to 21 of a 28-day cycle. Continue Kisqali treatment for as long as your doctor tells you to.

This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.

**If you take more Kisqali than you should**

If you take too many tablets, or if someone else takes your medicine, contact a doctor or hospital for advice immediately. Show the Kisqali packet. Medical treatment may be necessary.

**If you miss a dose of Kisqali**

If you vomit after taking the dose or forget a dose, skip the missed dose that day. Take the next dose at your usual time.

Do not take a double dose to make up for a missed dose. Instead, wait until it is time for your next scheduled dose and then take your usual dose.

**If you stop taking Kisqali**

Stopping your treatment with Kisqali may cause your condition to get worse. Do not stop taking Kisqali unless your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects could be serious
Tell your doctor immediately if you get any of the following symptoms during treatment with Kisqali:

- Fever, sweating or chills, cough, flu-like symptoms, weight loss, shortness of breath, blood in your phlegm, sores on your body, warm or painful areas on your body, diarrhoea or stomach pain, or feeling very tired (signs or symptoms of infections). **Very common (may affect more than 1 in 10 people)**.
- Fever, chills, weakness and frequent infections with symptoms such as sore throat or mouth ulcers (signs of a low level of leukocytes or lymphocytes, which are types of white blood cells). **Very common (may affect more than 1 in 10 people)**.
- Abnormal results of blood tests that give information about the health of the liver (abnormal liver function tests). **Very common (may affect more than 1 in 10 people)**.
- Spontaneous bleeding or bruising (signs of a low level of blood platelets). **Common (may affect up to 1 in 10 people)**.
- Sore throat or mouth ulcers with a single episode of fever of at least 38.3°C or fever above 38°C for more than one hour and/or with infection (febrile neutropenia). **Common (may affect up to 1 in 10 people)**.
- Tiredness, itchy yellow skin or yellowing of the whites of your eyes, nausea or vomiting, loss of appetite, pain in the upper right side of the belly (abdomen), dark or brown urine, bleeding or bruising more easily than normal (these may be signs of a liver problem). **Common (may affect up to 1 in 10 people)**.
- Reduced level of potassium in the blood, which could lead to disturbances in heart rhythm. **Common (may affect up to 1 in 10 people)**.
- Chest pain or discomfort, changes in heart beat (fast or slow), palpitations, lightheadedness, fainting, dizziness, lips turning blue colour, shortness of breath, swelling (oedema) of your lower limbs or skin (these may be signs of heart problems). **Common (may affect up to 1 in 10 people)**.
- Serious infection with increased heart rate, shortness of breath or rapid breathing, fever and chills (these may be signs of sepsis which is an infection in the blood system which may be life threatening). **Uncommon (may affect up to 1 in 100 people)**.
- Severe skin reaction that might include a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (toxic epidermal necrolysis [TEN]). **Frequency not known (frequency cannot be estimated from the available data)**.

Your doctor may ask you to take a lower dose, interrupt your treatment with Kisqali, or stop it permanently.
Other possible side effects
Other side effects include the following listed below. If these side effects become severe, tell your doctor, pharmacist or nurse.

**Very common (may affect more than 1 in 10 people)**
- Tiredness, pale skin (potential sign of a low level of red blood cells, anaemia)
- Sore throat, runny nose, fever (signs of a respiratory tract infection)
- Painful and frequent urination (signs of a urinary tract infection)
- Reduced appetite
- Headache
- Dizziness or light headedness
- Shortness of breath, difficulty breathing
- Cough
- Nausea (feeling sick)
- Diarrhoea
- Vomiting
- Constipation
- Abdominal (belly) pain
- Mouth sores with gum inflammation (stomatitis)
- Upset stomach, indigestion, heartburn (dyspepsia)
- Hair loss or hair thinning (alopecia)
- Rash
- Itching (pruritus)
- Back pain
- Tiredness (fatigue)
- Swollen hands, ankles or feet (peripheral oedema)
- Fever (pyrexia)
- Weakness (asthenia)

**Common (may affect up to 1 in 10 people)**
- Abdominal pain, nausea, vomiting and diarrhoea (signs of gastroenteritis, which is an infection of the gastrointestinal tract)
- Reduced level of calcium in the blood, which may sometimes lead to cramps
- Reduced level of phosphate in the blood
- Spinning sensation (vertigo)
- Watering eyes
- Dry eyes
- Reduced level of potassium in the blood, which could lead to disturbance in heart rhythm
- Strange taste in the mouth (dysgeusia)
- Dry skin
- Skin reddening (erythema)
- Loss of skin colour in patches (vitiligo)
- Sore throat (oropharyngeal pain)
- Dry mouth
- Abnormal kidney blood test result (high level of creatinine in the blood)

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. **How to store Kisqali**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not take this medicine if you notice any damage to the packaging or if there are any signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Kisqali contains**
- The active substance is ribociclib. Each film-coated tablet contains ribociclib succinate equivalent to 200 mg ribociclib.
- The other ingredients are:
  - Tablet core: microcrystalline cellulose; crospovidone type A; low-substituted hydroxypropylcellulose; magnesium stearate; colloidal anhydrous silica.
  - Coating material: iron oxide black (E172); iron oxide red (E172); soya lecithin (E322) (see “Kisqali contains soya lecithin” in section 2); polyvinyl alcohol (partially hydrolysed); talc; titanium dioxide (E171); xanthan gum.

**What Kisqali looks like and contents of the pack**
Kisqali is supplied as film-coated tablets in aluminum blisters.

The film-coated tablets are light greyish violet in colour, unscored, round, debossed with “RIC” on one side and “NVR” on the other side.

The following pack sizes are available: Packs containing 21, 42 or 63 film-coated tablets and multipacks containing 63 (3 packs of 21), 126 (3 packs of 42) or 189 (3 packs of 63) film-coated tablets.
Kisqali packs containing 63 tablets are intended for use by patients taking the full ribociclib daily dose of 600 mg (3 tablets once daily).
Kisqali packs containing 42 tablets are intended for use by patients taking the reduced ribociclib daily dose of 400 mg (2 tablets once daily).
Kisqali packs containing 21 tablets are intended for use by patients taking the lowest ribociclib daily dose of 200 mg (1 tablet once daily).

Not all pack sizes may be marketed.
**Marketing Authorisation Holder**
Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

**Manufacturer**
Novartis Pharma GmbH  
Roonstrasse 25  
90429 Nuremberg  
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Contact Information</th>
</tr>
</thead>
</table>
| België/Belgique/Belgien | Novartis Pharma N.V.  
Tél/Tel: +32 2 246 16 11 |
| България         | Novartis Bulgaria EOOD  
Tel: +359 2 489 98 28 |
| Česká republika | Novartis s.r.o.  
Tel: +420 225 775 111 |
| Danmark          | Novartis Healthcare A/S  
Tlf: +45 39 16 84 00 |
| Deutschland      | Novartis Pharma GmbH  
Tel: +49 911 273 0 |
| Естония         | SIA Novartis Baltics Eesti filiaal  
Tel: +372 66 30 810 |
| Ελλάδα           | Novartis (Hellas) A.E.B.E.  
Τηλ.: +30 210 281 17 12 |
| España           | Novartis Farmacéutica, S.A.  
Tel: +34 93 306 42 00 |
| France           | Novartis Pharma S.A.S.  
Tél: +33 1 55 47 66 00 |
| Hrvatska         | Novartis Hrvatska d.o.o.  
Tel. +385 1 6274 220 |
| Lietuva          | SIA Novartis Baltics Lietuvos filialas  
Tel: +370 5 269 16 50 |
| Luxemburg/Luxemburg | Novartis Pharma N.V.  
Tél/Tel: +32 2 246 16 11 |
| Magyarország     | Novartis Hungária Kft.  
Tel.: +36 1 457 65 00 |
| Malta            | Novartis Pharma Services Inc.  
Tel: +356 2122 2872 |
| Nederland        | Novartis Pharma B.V.  
Tel: +31 88 04 52 555 |
| Норвегия         | Novartis Norge AS  
Tlf: +47 23 05 20 00 |
| Österreich       | Novartis Pharma GmbH  
Tel: +43 1 86 6570 |
| Польша           | Novartis Poland Sp. z o.o.  
Tel.: +48 22 375 4888 |
| Португалия       | Novartis Farma - Produtos Farmacêuticos, S.A.  
Tel: +351 21 000 8600 |
| Романия          | Novartis Pharma Services Romania SRL  
Tel: +40 21 31299 01 |
Ireland  
Novartis Ireland Limited  
Tel: +353 1 260 12 55

Ísland  
Vistor hf.  
Sími: +354 535 7000

Italia  
Novartis Farma S.p.A.  
Tel: +39 02 96 54 1

Κύπρος  
Novartis Pharma Services Inc.  
Τηλ: +357 22 690 690

Latvija  
SIA Novartis Baltics  
Tel: +371 67 887 070

Slovenija  
Novartis Pharma Services Inc.  
Tel: +386 1 300 75 50

Slovenská republika  
Novartis Slovakia s.r.o.  
Tel: +421 2 5542 5439

Suomi/Finland  
Novartis Finland Oy  
Puh/Tel: +358 (0)10 6133 200

Sverige  
Novartis Sverige AB  
Tel: +46 8 732 32 00

United Kingdom (Northern Ireland)  
Novartis Ireland Limited  
Tel: +44 1276 698370

This leaflet was last revised in

Other sources of information  
Detailed information on this medicine is available on the European Medicines Agency web site:  
http://www.ema.europa.eu